<?xml version='1.0' encoding='utf-8'?>
<document id="15797798"><sentence text="In vitro plasma protein binding determination of flunarizine using equilibrium dialysis and liquid chromatography-tandem mass spectrometry."><entity charOffset="49-60" id="DDI-PubMed.15797798.s1.e0" text="flunarizine" /></sentence><sentence text="A highly sensitive method was developed and validated for determining the free fraction of flunarizine in human plasma"><entity charOffset="91-102" id="DDI-PubMed.15797798.s2.e0" text="flunarizine" /></sentence><sentence text=" Equilibrium dialysis was used for the separation of free (unbound) drug and liquid chromatography/tandem mass spectrometry (LC-MS/MS) was used for quantitation" /><sentence text=" Post-dialysis plasma or buffer samples of 0" /><sentence text="2 mL were extracted using a liquid-liquid extraction procedure and analyzed using a high performance liquid chromatography electrospray tandem mass spectrometer system" /><sentence text=" The compounds were eluted isocratically on a Supelco Supelcosil ABZ+Plus column, ionized using a positive ion atmospheric pressure electrospray ionization source, and analyzed using multiple reaction monitoring" /><sentence text=" The ion transitions monitored were m/z 405--&gt;203 for flunarizine and m/z 409--&gt;207 for flunarizine-d4 (internal standard, IS)"><entity charOffset="54-65" id="DDI-PubMed.15797798.s7.e0" text="flunarizine" /><entity charOffset="88-102" id="DDI-PubMed.15797798.s7.e1" text="flunarizine-d4" /><pair ddi="false" e1="DDI-PubMed.15797798.s7.e0" e2="DDI-PubMed.15797798.s7.e0" /><pair ddi="false" e1="DDI-PubMed.15797798.s7.e0" e2="DDI-PubMed.15797798.s7.e1" /></sentence><sentence text=" The chromatographic run time was 3" /><sentence text="5 min per injection, with retention times of 2" /><sentence text="1 min for both flunarizine and IS"><entity charOffset="15-26" id="DDI-PubMed.15797798.s10.e0" text="flunarizine" /></sentence><sentence text=" The calibration curve for flunarizine was linear over the concentration range of 0"><entity charOffset="27-38" id="DDI-PubMed.15797798.s11.e0" text="flunarizine" /></sentence><sentence text="25-2000 ng/mL (r(2)&gt;0" /><sentence text="9989) in the combined matrix of human plasma and isotonic sodium phosphate buffer (1:1, v/v) with the lower limit of quantitation of 0"><entity charOffset="58-74" id="DDI-PubMed.15797798.s13.e0" text="sodium phosphate" /></sentence><sentence text="25 ng/mL" /><sentence text=" The inter-assay coefficient of variability (CV) for the quality control samples was less than 13" /><sentence text="5%, and the inter-assay percent nominal was greater than 98" /><sentence text="2%" /><sentence text=" In vitro protein binding of flunarizine was determined at concentrations of 5, 10 and 100 microg/mL using the validated method"><entity charOffset="29-40" id="DDI-PubMed.15797798.s18.e0" text="flunarizine" /></sentence><sentence text=" Flunarizine was extensively bound to plasma protein with a 0"><entity charOffset="1-12" id="DDI-PubMed.15797798.s19.e0" text="Flunarizine" /></sentence><sentence text="083+/-0" /><sentence text="005% overall percent free drug in plasma and a CV value less than 7" /><sentence text="8%" /><sentence text=" This validated method will be used for the ex vivo assessment of flunarizine protein binding in human plasma from a drug-drug interaction clinical study"><entity charOffset="66-77" id="DDI-PubMed.15797798.s23.e0" text="flunarizine" /></sentence><sentence text="" /></document>